Symbols / BLRX
BLRX Chart
About
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 13.14M |
| Enterprise Value | 7.64B | Income | -2.98M | Sales | 12.73M |
| Book/sh | 0.01 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 28 | IPO | — |
| P/E | inf | Forward P/E | -3.08 | PEG | — |
| P/S | 1.03 | P/B | 400.00 | P/C | — |
| EV/EBITDA | -912.18 | EV/Sales | 599.60 | Quick Ratio | 1.90 |
| Current Ratio | 2.09 | Debt/Eq | 58.25 | LT Debt/Eq | — |
| EPS (ttm) | 0.00 | EPS next Y | -0.91 | EPS Growth | — |
| Revenue Growth | -91.40% | Earnings | 2026-03-31 | ROA | -13.60% |
| ROE | -21.24% | ROIC | — | Gross Margin | 50.70% |
| Oper. Margin | -5.17% | Profit Margin | -23.38% | Shs Outstand | 4.35M |
| Shs Float | 2.50B | Short Float | 3.99% | Short Ratio | 9.20 |
| Short Interest | — | 52W High | 7.77 | 52W Low | 2.30 |
| Beta | 0.46 | Avg Volume | 22.19K | Volume | 7.93K |
| Target Price | $20.33 | Recom | None | Prev Close | $2.93 |
| Price | $2.80 | Change | -4.44% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$20.33
Mean price target
2. Current target
$2.81
Latest analyst target
3. DCF / Fair value
$-28.20
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.81
Low
$12.00
High
$26.00
Mean
$20.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-06-17 | reit | HC Wainwright & Co. | Buy → Buy | $26 |
| 2025-05-30 | up | Jones Trading | Hold → Buy | $12 |
| 2025-05-28 | reit | HC Wainwright & Co. | Buy → Buy | $26 |
| 2025-04-02 | down | Jones Trading | Buy → Hold | — |
| 2025-03-31 | main | HC Wainwright & Co. | Buy → Buy | $26 |
| 2024-11-25 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-11-06 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-06-03 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-05-29 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-04-17 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-03-26 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-02-29 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2023-11-20 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2023-09-15 | main | HC Wainwright & Co. | Buy → Buy | $21 |
| 2023-08-31 | reit | HC Wainwright & Co. | Buy → Buy | $19 |
| 2023-05-25 | reit | Oppenheimer | — → Outperform | $4 |
| 2021-02-23 | main | HC Wainwright & Co. | — → Buy | $19 |
| 2020-12-16 | main | HC Wainwright & Co. | — → Buy | $22 |
| 2017-08-04 | init | Oppenheimer | — → Outperform | $3 |
| 2017-05-18 | up | Maxim Group | Hold → Buy | — |
- BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire Mon, 24 Nov 2025 08
- H.C. Wainwright Reaffirms Buy on BioLineRx Ltd. (BLRX) After ASCO 2025 - MSN hu, 12 Feb 2026 08
- Hemispherian (BLRX) Gets USPTO Allowance for GLIX1 Patent Covering Most Solid Tumors - Stock Titan Wed, 19 Nov 2025 08
- BioLineRx Announces $6 Million Registered Direct Offering - Intellectia AI Sun, 15 Feb 2026 22
- BioLineRx stock rises after partner receives key patent allowance - Investing.com Wed, 19 Nov 2025 08
- Is BLRX stock forming a triangle pattern - 2025 Biggest Moves & Growth Focused Entry Point Reports - mfd.ru Sun, 15 Feb 2026 01
- 3 Stocks Getting Rare Double Upgrades From Analysts - MarketBeat Fri, 06 Jun 2025 07
- BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire hu, 14 Aug 2025 07
- Pre-Market Earnings Report for November 24, 2025 : CAAP, BLRX - Nasdaq Fri, 21 Nov 2025 08
- BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers - Intellectia AI Mon, 16 Feb 2026 01
- BioLineRx Q1 Earnings Rise Despite Fall In Revenue: Retail Stays Super Confident - Stocktwits ue, 27 May 2025 18
- BioLineRx stock rises after securing key patent for cancer treatment - Investing.com Mon, 17 Nov 2025 08
- BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire ue, 27 May 2025 07
- 3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond - Yahoo Finance Sun, 25 Feb 2024 08
- BioLineRx Reports 2024 Financial Results and Provides Corporate Update - PR Newswire Mon, 31 Mar 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -13.84M | -39.39M | -28.59M | -23.71M |
| TotalUnusualItems | 17.76M | -17.70M | 6.08M | -1.65M |
| TotalUnusualItemsExcludingGoodwill | 17.76M | -17.70M | 6.08M | -1.65M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -9.22M | -60.61M | -24.95M | -27.05M |
| ReconciledDepreciation | 4.07M | 1.38M | 654.00K | 703.00K |
| ReconciledCostOfRevenue | 5.54M | 2.66M | 0.00 | 0.00 |
| EBITDA | 3.92M | -57.09M | -22.51M | -25.37M |
| EBIT | -147.00K | -58.47M | -23.16M | -26.07M |
| NetInterestIncome | -7.30M | -162.00K | -1.12M | -729.00K |
| InterestExpense | 9.07M | 2.14M | 1.79M | 984.00K |
| InterestIncome | 1.82M | 2.01M | 694.00K | 277.00K |
| NormalizedIncome | -26.98M | -42.92M | -31.03M | -25.40M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -9.22M | -60.61M | -24.95M | -27.05M |
| TotalExpenses | 48.09M | 47.79M | 29.16M | 24.78M |
| TotalOperatingIncomeAsReported | -20.41M | -49.69M | -29.16M | -24.78M |
| DilutedAverageShares | 2.00M | 1.61M | 1.29M | 1.10M |
| BasicAverageShares | 2.00M | 1.61M | 1.29M | 1.10M |
| DilutedEPS | -6.00 | -36.00 | -18.00 | -24.00 |
| BasicEPS | -6.00 | -36.00 | -18.00 | -24.00 |
| DilutedNIAvailtoComStockholders | -9.22M | -60.61M | -24.95M | -27.05M |
| NetIncomeCommonStockholders | -9.22M | -60.61M | -24.95M | -27.05M |
| NetIncome | -9.22M | -60.61M | -24.95M | -27.05M |
| NetIncomeIncludingNoncontrollingInterests | -9.22M | -60.61M | -24.95M | -27.05M |
| NetIncomeContinuousOperations | -9.22M | -60.61M | -24.95M | -27.05M |
| PretaxIncome | -9.22M | -60.61M | -24.95M | -27.05M |
| OtherIncomeExpense | 17.23M | -17.46M | 5.32M | -1.55M |
| OtherNonOperatingIncomeExpenses | -530.00K | 235.00K | -755.00K | 106.00K |
| SpecialIncomeCharges | -1.26M | -6.70M | 0.00 | 0.00 |
| OtherSpecialCharges | 246.00K | |||
| ImpairmentOfCapitalAssets | 1.01M | 6.70M | 0.00 | 0.00 |
| GainOnSaleOfSecurity | 19.02M | -10.99M | 6.08M | -1.65M |
| NetNonOperatingInterestIncomeExpense | -7.30M | -162.00K | -1.12M | -729.00K |
| TotalOtherFinanceCost | 45.00K | 25.00K | 26.00K | 22.00K |
| InterestExpenseNonOperating | 9.07M | 2.14M | 1.79M | 984.00K |
| InterestIncomeNonOperating | 1.82M | 2.01M | 694.00K | 277.00K |
| OperatingIncome | -19.15M | -42.99M | -29.16M | -24.78M |
| OperatingExpense | 38.83M | 44.10M | 29.16M | 24.78M |
| ProvisionForDoubtfulAccounts | 800.00K | 0.00 | 0.00 | |
| DepreciationAmortizationDepletionIncomeStatement | 340.00K | 351.00K | 39.00K | 42.00K |
| DepreciationAndAmortizationInIncomeStatement | 340.00K | 351.00K | 39.00K | 42.00K |
| DepreciationIncomeStatement | 340.00K | 351.00K | 39.00K | 42.00K |
| ResearchAndDevelopment | 9.15M | 12.52M | 17.63M | 19.47M |
| SellingGeneralAndAdministration | 28.54M | 31.23M | 11.49M | 5.27M |
| SellingAndMarketingExpense | 10.08M | 14.59M | 4.88M | 754.00K |
| GeneralAndAdministrativeExpense | 18.46M | 16.64M | 6.61M | 4.51M |
| OtherGandA | 2.75M | 3.18M | 1.90M | 1.21M |
| InsuranceAndClaims | 808.00K | 939.00K | 1.05M | 1.06M |
| SalariesAndWages | 14.91M | 12.52M | 3.66M | 2.24M |
| GrossProfit | 19.68M | 1.11M | 0.00 | 0.00 |
| CostOfRevenue | 9.26M | 3.69M | 0.00 | 0.00 |
| TotalRevenue | 28.94M | 4.80M | 0.00 | 0.00 |
| OperatingRevenue | 28.94M | 4.80M | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 1.34B | 1.09B | 922.96M | 715.16M |
| ShareIssued | 1.34B | 1.09B | 922.96M | 715.16M |
| NetDebt | 3.00M | 5.52M | ||
| TotalDebt | 15.04M | 11.59M | 12.32M | 4.65M |
| TangibleBookValue | 3.01M | -1.63M | 28.96M | 46.38M |
| InvestedCapital | 26.90M | 23.00M | 61.01M | 70.84M |
| WorkingCapital | 11.70M | 4.40M | 41.32M | 47.69M |
| NetTangibleAssets | 3.01M | -1.63M | 28.96M | 46.38M |
| CapitalLeaseObligations | 1.60M | 1.82M | 2.16M | 1.89M |
| CommonStockEquity | 13.46M | 13.22M | 50.84M | 68.09M |
| TotalCapitalization | 22.42M | 19.85M | 59.47M | 68.09M |
| TotalEquityGrossMinorityInterest | 13.46M | 13.22M | 50.84M | 68.09M |
| StockholdersEquity | 13.46M | 13.22M | 50.84M | 68.09M |
| OtherEquityInterest | 5.37M | 1.41M | 1.41M | 975.00K |
| GainsLossesNotAffectingRetainedEarnings | 16.13M | 15.58M | 13.35M | 11.74M |
| OtherEquityAdjustments | 16.13M | 15.58M | 13.35M | 11.74M |
| RetainedEarnings | -399.83M | -390.61M | -329.99M | -305.04M |
| AdditionalPaidInCapital | 353.69M | 355.48M | 338.98M | 339.35M |
| CapitalStock | 38.10M | 31.36M | 27.10M | 21.07M |
| CommonStock | 38.10M | 31.36M | 27.10M | 21.07M |
| TotalLiabilitiesNetMinorityInterest | 25.45M | 50.70M | 25.54M | 13.30M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 10.04M | 7.92M | 14.86M | 3.58M |
| DerivativeProductLiabilities | 11.93M | 4.51M | 1.86M | |
| LongTermDebtAndCapitalLeaseObligation | 10.04M | 7.92M | 10.36M | 1.73M |
| LongTermCapitalLeaseObligation | 1.08M | 1.29M | 1.73M | 1.73M |
| LongTermDebt | 8.96M | 6.63M | 8.63M | |
| CurrentLiabilities | 15.41M | 42.78M | 10.68M | 9.72M |
| OtherCurrentLiabilities | 1.69M | 11.93M | ||
| CurrentDeferredLiabilities | 0.00 | 12.96M | 0.00 | |
| CurrentDeferredRevenue | 0.00 | 12.96M | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 5.00M | 3.67M | 1.97M | 2.92M |
| CurrentCapitalLeaseObligation | 522.00K | 528.00K | 427.00K | 168.00K |
| CurrentDebt | 4.48M | 3.15M | 1.54M | 2.76M |
| OtherCurrentBorrowings | 4.48M | 3.15M | 1.54M | 2.76M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 431.00K | 419.00K | 377.00K | 397.00K |
| PayablesAndAccruedExpenses | 8.28M | 13.80M | 8.33M | 6.40M |
| CurrentAccruedExpenses | 2.70M | 2.85M | 1.28M | 828.00K |
| Payables | 5.58M | 10.96M | 7.05M | 5.57M |
| OtherPayable | 88.00K | 84.00K | 2.00K | |
| AccountsPayable | 5.58M | 10.87M | 6.97M | 5.57M |
| TotalAssets | 38.91M | 63.92M | 76.38M | 81.39M |
| TotalNonCurrentAssets | 11.80M | 16.74M | 24.38M | 23.99M |
| GoodwillAndOtherIntangibleAssets | 10.45M | 14.85M | 21.89M | 21.70M |
| OtherIntangibleAssets | 10.45M | 14.85M | 21.89M | 21.70M |
| NetPPE | 1.35M | 1.89M | 2.50M | 2.28M |
| AccumulatedDepreciation | -4.98M | -5.54M | -4.78M | -4.54M |
| GrossPPE | 6.33M | 7.43M | 7.28M | 6.82M |
| Leases | 3.59M | 4.13M | 4.13M | 3.58M |
| OtherProperties | 1.57M | 1.61M | 1.61M | 1.59M |
| MachineryFurnitureEquipment | 1.17M | 1.68M | 1.54M | 1.65M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 27.10M | 47.18M | 52.00M | 57.40M |
| PrepaidAssets | 534.00K | 1.53M | 198.00K | 127.00K |
| Inventory | 3.15M | 1.95M | 0.00 | |
| FinishedGoods | 165.00K | 579.00K | 0.00 | |
| WorkInProcess | 2.98M | 471.00K | 0.00 | |
| RawMaterials | 0.00 | 903.00K | 0.00 | |
| Receivables | 3.86M | 708.00K | 721.00K | 142.00K |
| OtherReceivables | 1.39M | 350.00K | 721.00K | 142.00K |
| AccountsReceivable | 2.48M | 358.00K | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 19.56M | 42.99M | 51.08M | 57.13M |
| OtherShortTermInvestments | 9.13M | 38.74M | 40.49M | 44.15M |
| CashAndCashEquivalents | 10.44M | 4.25M | 10.59M | 12.99M |
| CashEquivalents | 9.49M | 1.10M | 6.96M | 4.53M |
| CashFinancial | 944.00K | 3.15M | 3.62M | 8.46M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -43.93M | -22.91M | -26.56M | -23.67M |
| RepaymentOfDebt | -14.94M | -1.99M | -3.05M | -3.57M |
| IssuanceOfDebt | 19.22M | 0.00 | 9.13M | 0.00 |
| IssuanceOfCapitalStock | 16.36M | 14.09M | 14.36M | 50.41M |
| CapitalExpenditure | -54.00K | -297.00K | -316.00K | -97.00K |
| InterestPaidSupplementalData | 10.39M | 1.11M | 593.00K | 682.00K |
| EndCashPosition | 10.44M | 4.25M | 10.59M | 12.99M |
| BeginningCashPosition | 4.25M | 10.59M | 12.99M | 16.83M |
| EffectOfExchangeRateChanges | 22.00K | -224.00K | -607.00K | 207.00K |
| ChangesInCash | 6.16M | -6.11M | -1.80M | -4.05M |
| FinancingCashFlow | 20.66M | 15.06M | 20.44M | 57.75M |
| CashFlowFromContinuingFinancingActivities | 20.66M | 15.06M | 20.44M | 57.75M |
| ProceedsFromStockOptionExercised | 22.00K | 2.96M | 5.00K | 10.91M |
| NetCommonStockIssuance | 16.36M | 14.09M | 14.36M | 50.41M |
| CommonStockIssuance | 16.36M | 14.09M | 14.36M | 50.41M |
| NetIssuancePaymentsOfDebt | 4.28M | -1.99M | 6.07M | -3.57M |
| NetLongTermDebtIssuance | 4.28M | -1.99M | 6.07M | -3.57M |
| LongTermDebtPayments | -14.94M | -1.99M | -3.05M | -3.57M |
| LongTermDebtIssuance | 19.22M | 0.00 | 9.13M | 0.00 |
| InvestingCashFlow | 29.37M | 1.44M | 4.01M | -38.22M |
| CashFlowFromContinuingInvestingActivities | 29.37M | 1.44M | 4.01M | -38.22M |
| NetInvestmentPurchaseAndSale | 29.43M | 1.74M | 4.32M | -38.13M |
| SaleOfInvestment | 55.78M | 49.33M | 48.32M | 39.87M |
| PurchaseOfInvestment | -26.35M | -47.59M | -44.00M | -78.00M |
| NetIntangiblesPurchaseAndSale | -1.00K | -181.00K | -185.00K | 0.00 |
| PurchaseOfIntangibles | -1.00K | -181.00K | -185.00K | 0.00 |
| NetPPEPurchaseAndSale | -53.00K | -116.00K | -131.00K | -97.00K |
| PurchaseOfPPE | -53.00K | -116.00K | -131.00K | -97.00K |
| OperatingCashFlow | -43.87M | -22.61M | -26.24M | -23.57M |
| CashFlowFromContinuingOperatingActivities | -43.87M | -22.61M | -26.24M | -23.57M |
| ChangeInWorkingCapital | -21.82M | 15.20M | 1.24M | -540.00K |
| ChangeInOtherWorkingCapital | -12.96M | 12.96M | ||
| ChangeInPayablesAndAccruedExpense | -5.51M | 5.51M | 1.89M | -564.00K |
| ChangeInPrepaidAssets | -43.00K | -959.00K | -650.00K | 24.00K |
| ChangeInInventory | -1.19M | -1.95M | 0.00 | 0.00 |
| ChangeInReceivables | -2.12M | -358.00K | 0.00 | 0.00 |
| ChangesInAccountReceivables | -2.12M | -358.00K | 0.00 | 0.00 |
| OtherNonCashItems | -941.00K | 1.16M | 445.00K | 39.00K |
| StockBasedCompensation | 1.14M | 2.32M | 2.25M | 1.50M |
| AssetImpairmentCharge | 1.26M | 6.70M | 0.00 | 0.00 |
| DepreciationAmortizationDepletion | 4.07M | 1.38M | 654.00K | 703.00K |
| DepreciationAndAmortization | 4.07M | 1.38M | 654.00K | 703.00K |
| OperatingGainsLosses | -18.35M | 11.24M | -5.87M | 1.78M |
| GainLossOnInvestmentSecurities | -18.30M | 11.05M | -6.25M | 1.94M |
| NetForeignCurrencyExchangeGainLoss | -53.00K | 182.00K | 383.00K | -152.00K |
| NetIncomeFromContinuingOperations | -9.22M | -60.61M | -24.95M | -27.05M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for BLRX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|